Nektar Therapeutics | NKTR - 普通股股本



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 10.87B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


普通股股本 更改 日
Agios Pharmaceuticals USD 59.34M 892K 2026-03
ALKERMES USD 166.46M 855K 2026-03
Alterity Therapeutics Limited AUD 10.88B 10.66B 2025-12
Amgen USD 540M 1000K 2026-03
Baxter International USD 516.45M 2.17M 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cara Therapeutics USD 9.38M 9.38M 2025-09
Cipla INR 807.78M 17K 2026-03
Dr.Reddys Laboratories INR 832.69M 176K 2026-03
Eisai JPY 282.11M 0 2026-03
Eli Lilly USD 943.5M 3.33M 2026-03
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Exelixis USD 253.7M 8.78M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
Grifols EUR 680.58M 846.11K 2025-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Ironwood Pharmaceuticals USD 160K 0 2024-12
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
MacroGenics USD 63.32M 60K 2025-12
Merck USD 2.47B 12.72M 2025-12
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novartis USD 1.91B 60K 2026-03
Pfizer USD 5.7B 13M 2026-03
Roche Holding CHF 795.62M 699.54K 2025-12
Sarepta Therapeutics USD 105.57M 607K 2026-03
Takeda JPY 1.58B 241K 2026-03
Teva Pharmaceutical Industries USD 1.16B 16.72M 2026-03
Xencor USD 74.06M 2.19M 2026-03